Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- A New Index Of Emerging Biotech And Pharma Companies
Nov 22, 2008 08:25 PM
- Rigel Pharmaceuticals– Crisis Or Opportunity?
Nov 10, 2008 09:57 AM
- Earnings Preview For Nov 3 - 7 - Earnings Preview
Oct 31, 2008 10:03 PM
- Analyst Comments: Procter & Gamble, CV Therapeutics, BHP Billiton, Chunghwa, Anheuser-Busch, Texas Capital, CSX Corp, Barrick Gold, Willis Group
Sep 17, 2008 01:06 PM
- Transportation and Biotech: Stocks On The Rise
Sep 16, 2008 01:00 PM
- FDA Calendar: Buy CV Therapeutics and Sell Noven Pharma
Aug 07, 2008 02:05 AM
- Analyst Comments: Conseco, CV Therapeutics, CNOOC, WPP Group, Triumph
Aug 05, 2008 12:00 PM
- Few Thoughts and a Look at the Earnings in the Coming Week
Jul 28, 2008 01:20 AM
- Analyst Comments: Merck, CV Therapeutics, Stoneridge, Eastman Chemical, National Semi, CAI International, Beacon Roofing
Jun 13, 2008 12:13 PM
- Media Digest for 5/12
May 12, 2008 10:02 AM
- Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: CCE, KSS, CVTX, SLG, LPNT, TEF
Nov 11, 2008 11:52 AM
- CV Therapeutics Reports 2008 Third Quarter Financial Results
Nov 06, 2008 06:02 AM
- FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
Nov 06, 2008 06:01 AM
- CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008
Oct 23, 2008 08:30 AM
- CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2008
Oct 21, 2008 08:31 AM
- CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
Sep 12, 2008 06:01 AM
- CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
Sep 02, 2008 08:31 AM
- CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
Aug 27, 2008 04:02 PM
- Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improved Cardiac Relaxation in Study of Patients With Long QT Syndrome
Aug 19, 2008 08:31 AM
- CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
Aug 14, 2008 04:01 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
CVTX
|
Compare to S&P
|
| YTD |
0.11 %
|
64.02 %
|
| 4 Weeks |
-2.89 %
|
4.96 %
|
| 12 Weeks |
-20.80 %
|
9.78 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -485.71 %
|
|
EPS Growth in Last Year: 28.07 %
|
|
Sales Growth in Last Quarter: -26.15 %
|
|
Sales Growth in Last Quarter: 92.89 %
|
|
|
